Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARDX

Ardelyx Inc

Dec 13 • 04:00PM ET

5.22

Dollar change -0.02
Percentage change -0.38	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX NBIX ENTA BMRN EXEL AKTX SRPT IRWD

| Held by: VTI IWM XBI VXF IWO VTWO SCHA VHT SURI LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.31	Insider Own	3.78%	Shs Outstand	236.89M	Perf Week	-8.74%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-0.07	Insider Trans	-3.36%	Shs Float	227.89M	Perf Month	16.00%
Income	-72.58M	PEG	-	EPS next Q	0.01	Inst Own	61.53%	Short Float	10.67%	Perf Quarter	-16.08%
Sales	251.85M	P/S	4.89	EPS this Y	41.17%	Inst Trans	3.30%	Short Ratio	6.07	Perf Half Y	-17.80%
Book/sh	0.67	P/B	7.81	EPS next Y	62.70%	ROA	-22.09%	Short Interest	24.32M	Perf Year	-4.74%
Cash/sh	0.81	P/C	6.47	EPS next 5Y	30.00%	ROE	-41.54%	52W Range	4.34 - 10.13	Perf YTD	-15.81%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.61%	ROI	-27.89%	52W High	-48.47%	Beta	0.83
Dividend TTM	-	Quick Ratio	3.87	Sales past 5Y	146.90%	Gross Margin	84.40%	52W Low	20.26%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	4.03	EPS Y/Y TTM	-151.94%	Oper. Margin	-25.44%	RSI (14)	45.08	Volatility	5.33% 5.93%
Employees	267	Debt/Eq	0.66	Sales Y/Y TTM	87.57%	Profit Margin	-28.82%	Recom	1.40	Target Price	10.78
Option/Short	Yes / Yes	LT Debt/Eq	0.64	EPS Q/Q	-111.68%	Payout	-	Rel Volume	0.53	Prev Close	5.24
Sales Surprise	13.39%	EPS Surprise	100.00%	Sales Q/Q	74.21%	Earnings	Oct 31 AMC	Avg Volume	4.01M	Price	5.22
SMA20	-1.69%	SMA50	-6.59%	SMA200	-18.84%	Trades		Volume	2,123,599	Change	-0.38%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$11 → $5.50
Jul-02-24	Downgrade	Piper Sandler	Overweight → Neutral	$15 → $7
Apr-05-24	Initiated	Leerink Partners	Outperform	$14
Dec-18-23	Initiated	Raymond James	Strong Buy	$12
Sep-07-23	Initiated	H.C. Wainwright	Buy	$9
Aug-25-23	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$5 → $10
Mar-03-23	Upgrade	Wedbush	Neutral → Outperform	$3 → $6
Nov-17-22	Upgrade	Piper Sandler	Neutral → Overweight	$3 → $8
May-06-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$7 → $1
Dec-01-21	Upgrade	Ladenburg Thalmann	Neutral → Buy	$6
Oct-14-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Jul-21-21	Downgrade	Jefferies	Buy → Hold	$11 → $2
Jul-20-21	Downgrade	Wedbush	Outperform → Neutral	$3
Jul-20-21	Downgrade	Piper Sandler	Overweight → Neutral	$14 → $4
Mar-23-21	Initiated	Wedbush	Outperform	$14
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$14
Oct-20-20	Resumed	Citigroup	Buy	$13
Feb-18-20	Resumed	Jefferies	Buy	$11
Feb-12-20	Initiated	Citigroup	Buy	$13
Feb-10-20	Initiated	Cowen	Outperform

Show Previous Ratings

Nov-20-24 08:00AM	Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:31PM	Ardelyx Responds to District Court Decision Granting Motion to Dismiss (GlobeNewswire) -20.53%
Nov-05-24 08:00AM	Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-01-24 10:04AM	Q3 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... (GuruFocus.com)
05:30PM	Loading…
Oct-31-24 05:30PM	Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
04:22PM	Ardelyx: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 04:05PM	Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting (GlobeNewswire)
Oct-24-24 04:05PM	Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH (tenapanor) at the American Society of Nephrology's Kidney Week (GlobeNewswire) +5.02%
10:01AM	Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline (Zacks)
Oct-22-24 04:05PM	Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community (GlobeNewswire)
Oct-21-24 04:05PM	Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community (GlobeNewswire)
Oct-18-24 09:55AM	Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher (Zacks)
08:00AM	Loading…
Oct-17-24 08:00AM	Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week (GlobeNewswire)
Oct-11-24 09:00AM	Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CXM (PR Newswire)
Oct-09-24 03:53PM	Ardelyx Inc (ARDX) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Challenges (GuruFocus.com)
12:46PM	Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
08:05AM	Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology (GlobeNewswire)
Oct-07-24 09:55AM	Wall Street Analysts Think Ardelyx (ARDX) Could Surge 65.4%: Read This Before Placing a Bet (Zacks) -10.12%
Oct-03-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ARDX (PR Newswire)
Sep-30-24 01:02PM	Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
Sep-10-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX (PR Newswire)
Sep-06-24 05:45AM	Ardelyx, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights - ARDX (PR Newswire)
Sep-05-24 08:00AM	Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-28-24 12:43PM	Ardelyx, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your Rights ARDX (GlobeNewswire)
Aug-08-24 08:00AM	Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer (GlobeNewswire) +5.77%
Aug-01-24 07:30PM	Here's What Key Metrics Tell Us About Ardelyx (ARDX) Q2 Earnings (Zacks) +10.00%
05:45PM	Loading…
05:45PM	Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:42PM	Ardelyx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 08:02AM	Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH (tenapanor) Clinical Trials in Current Medical Research and Opinion (GlobeNewswire)
Jul-25-24 10:01AM	Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-18-24 02:53PM	Ardelyx sues CMS over revamped kidney disease drug payment bundle (Pharmaceutical Technology)
08:00AM	Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024 (GlobeNewswire)
Jul-17-24 05:10PM	Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines (GlobeNewswire) -7.41%
Jul-02-24 07:00AM	To Preserve Patient Access to XPHOZAH , Ardelyx Chooses Not to File for TDAPA (GlobeNewswire) -30.25%
Jun-28-24 08:17AM	Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines (GlobeNewswire) +14.00%
Jun-24-24 07:30AM	3 Promising Penny Stocks for the Most Astute Investors (InvestorPlace)
Jun-16-24 06:17AM	3 Stocks Under $10 With the Potential to Make You a Millionaire (InvestorPlace)
May-30-24 04:02PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-22-24 08:02AM	Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-21-24 08:02AM	Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA (tenapanor), a First-In-Class Treatment for IBS-C in Adults (GlobeNewswire)
May-19-24 04:00PM	The 3 Best Penny Stocks to Buy in May 2024 (InvestorPlace)
May-16-24 08:01AM	Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH (tenapanor) (GlobeNewswire)
May-15-24 04:30PM	7 Cheap Penny Stocks to Buy Now: May 2024 (InvestorPlace)
May-14-24 04:02PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
May-09-24 04:43PM	Ardelyx Insider Sold Shares Worth $2,522,217, According to a Recent SEC Filing (MT Newswires)
May-07-24 05:00PM	Ardelyx Insider Sold Shares Worth $333,574, According to a Recent SEC Filing (MT Newswires) -8.92%
08:01AM	Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference (GlobeNewswire)
May-04-24 11:00AM	Ardelyx, Inc. (NASDAQ:ARDX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 02:16PM	Ardelyx Shares Rise After Q1 Beat (MT Newswires) +28.42%
09:57AM	Wedbush Adjusts Ardelyx's Price Target to $15 From $14, Keeps Outperform Rating (MT Newswires)
07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:21AM	Q1 2024 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents)
May-02-24 08:58PM	ARDX Stock Earnings: Ardelyx Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:45PM	Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Ardelyx: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 08:00AM	Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings (GlobeNewswire)
Apr-25-24 10:02AM	Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-18-24 08:00AM	Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 (GlobeNewswire)
Apr-02-24 11:34AM	The Millionaires Shortcut: 3 Stocks to Transform Your Portfolio This Month (InvestorPlace)
Mar-28-24 04:05PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Mar-25-24 08:00AM	Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy (GlobeNewswire)
Mar-16-24 06:00PM	The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter (InvestorPlace)
Mar-12-24 04:35PM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Feb-28-24 05:40PM	The Millionaires Watchlist: 3 Stocks Set for a Meteoric Rise (InvestorPlace)
Feb-27-24 08:00AM	Ardelyx to Participate at the Cowen 44th Annual Health Care Conference (GlobeNewswire)
06:10AM	Stocks on the Launchpad: The Next 3 Market Sensations (InvestorPlace)
Feb-23-24 10:16AM	Ardelyx, Inc. (NASDAQ:ARDX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 06:00PM	Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:45PM	Ardelyx Inc (ARDX) Reports Robust Revenue Growth and Strategic Advances in 2023 (GuruFocus.com)
04:26PM	Ardelyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-19-24 03:30PM	Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024 (InvestorPlace)
12:24PM	3 Revolutionary Biotech Stocks Poised for 10X Surge (InvestorPlace)
Feb-15-24 10:00AM	Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-09-24 09:55AM	Wall Street Analysts Believe Ardelyx (ARDX) Could Rally 34.84%: Here's is How to Trade (Zacks) +5.07%
08:50AM	Ardelyx (ARDX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-08-24 12:16PM	3 Unstoppable Russell 2000 to Buy in February (InvestorPlace)
12:00PM	Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:40AM	Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-07-24 09:34AM	3 Sleeper Stocks Under $15 Ready to Explode by 2029 (InvestorPlace)
Feb-06-24 04:00PM	3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List (InvestorPlace)
Feb-02-24 02:15AM	The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 (InvestorPlace)
Feb-01-24 08:00AM	Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024 (GlobeNewswire) +6.41%
Jan-29-24 12:35PM	3 Groundbreaking Biotech Stocks to Invest in Now (InvestorPlace)
Jan-12-24 07:56AM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire)
Jan-10-24 02:27PM	The 3 Best Under-$10 Stocks to Buy in January 2024 (InvestorPlace)
Jan-08-24 08:00AM	Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities (GlobeNewswire) +32.79%
Jan-03-24 08:03AM	Ardelyx to Provide Company Update on IBSRELA and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 (GlobeNewswire)
Dec-29-23 11:01PM	Insider Sell: CFO Justin Renz Sells 225,000 Shares of Ardelyx Inc (ARDX) (GuruFocus.com)
Dec-20-23 08:00AM	Ardelyx, Inc. Reports Employment Inducement Grants (GlobeNewswire) -10.54%
Dec-14-23 06:40AM	3 Short-Squeeze Stocks Ready for a Year-End Rally (InvestorPlace) +5.84%
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RAAB MICHAEL	President & CEO	Dec 10 '24	Option Exercise	0.99	25,000	24,750	1,175,385	Dec 12 07:02 PM
RAAB MICHAEL	President & CEO	Dec 10 '24	Sale	5.26	25,000	131,620	1,150,385	Dec 12 07:02 PM
MICHAEL G. RAAB	Officer	Dec 10 '24	Proposed Sale	5.26	25,000	131,618		Dec 10 04:09 PM
RAAB MICHAEL	President & CEO	Nov 25 '24	Sale	5.38	25,000	134,482	1,150,385	Nov 27 08:15 PM
MICHAEL G. RAAB	Officer	Nov 25 '24	Proposed Sale	5.38	25,000	134,480		Nov 25 04:15 PM
Williams Laura A	Chief Medical Officer	Nov 20 '24	Sale	4.79	7,366	35,316	308,745	Nov 22 06:37 PM
Rosenbaum David P.	Chief Development Officer	Nov 20 '24	Sale	4.79	4,941	23,690	297,005	Nov 22 06:34 PM
Rosenbaum David P.	Chief Development Officer	Nov 20 '24	Sale	4.79	2,243	10,754	151,373	Nov 22 06:34 PM
Renz Justin A	Chief Financial Officer	Nov 20 '24	Sale	4.79	5,260	25,219	291,139	Nov 22 06:33 PM
RAAB MICHAEL	President & CEO	Nov 20 '24	Sale	4.79	31,980	153,328	1,175,385	Nov 22 06:31 PM
GRAMMER ELIZABETH A	See Remarks	Nov 20 '24	Sale	4.79	7,046	33,782	185,334	Nov 22 06:24 PM
Blanks Robert	See Remarks	Nov 20 '24	Sale	4.79	4,941	23,690	314,421	Nov 22 06:22 PM
MOTT DAVID M	Director	Nov 13 '24	Buy	4.62	215,868	996,598	1,425,465	Nov 14 04:26 PM
RAAB MICHAEL	President & CEO	Nov 11 '24	Sale	4.90	2,743	13,441	1,207,365	Nov 12 05:00 PM
MICHAEL G. RAAB	Officer	Nov 11 '24	Proposed Sale	4.90	2,743	13,441		Nov 12 11:44 AM
Rosenbaum David P.	Chief Development Officer	Nov 06 '24	Option Exercise	2.32	27,171	63,037	180,787	Nov 08 06:00 PM
Rosenbaum David P.	Chief Development Officer	Nov 06 '24	Sale	6.10	27,171	165,743	153,616	Nov 08 06:00 PM
Rosenbaum David P.	Chief Development Officer	Nov 04 '24	Option Exercise	2.32	27,172	63,039	180,788	Nov 06 05:59 PM
Rosenbaum David P.	Chief Development Officer	Nov 04 '24	Sale	5.95	27,172	161,673	153,616	Nov 06 05:59 PM
RAAB MICHAEL	President & CEO	Oct 28 '24	Option Exercise	0.99	25,000	24,750	1,235,108	Oct 31 08:24 AM
RAAB MICHAEL	President & CEO	Oct 28 '24	Sale	5.91	25,000	147,740	1,210,108	Oct 31 08:24 AM
MICHAEL G. RAAB	Officer	Oct 28 '24	Proposed Sale	5.91	25,000	147,740		Oct 28 04:14 PM
RAAB MICHAEL	President & CEO	Oct 11 '24	Sale	6.01	7,500	45,075	1,210,108	Oct 15 05:01 PM
MICHAEL G. RAAB	Officer	Oct 11 '24	Proposed Sale	6.01	7,500	45,075		Oct 11 04:16 PM
Rosenbaum David P.	Chief Development Officer	Sep 27 '24	Sale	6.92	49,564	342,983	301,946	Oct 01 04:34 PM
DAVID P ROSENBAUM	Officer	Sep 27 '24	Proposed Sale	6.36	49,564	315,227		Sep 27 04:26 PM
RAAB MICHAEL	President & CEO	Sep 26 '24	Sale	6.07	3,000	18,210	1,217,608	Sep 27 04:09 PM
MICHAEL G. RAAB	Officer	Sep 26 '24	Proposed Sale	6.07	3,000	18,210		Sep 26 04:10 PM
Rosenbaum David P.	Chief Development Officer	Sep 13 '24	Sale	6.26	5,312	33,254	153,616	Sep 16 06:14 PM
RAAB MICHAEL	President & CEO	Sep 11 '24	Option Exercise	0.99	35,000	34,650	1,255,608	Sep 13 04:35 PM
RAAB MICHAEL	President & CEO	Sep 11 '24	Sale	5.61	35,000	196,399	1,220,608	Sep 13 04:35 PM
MICHAEL G. RAAB	Officer	Sep 11 '24	Proposed Sale	5.61	35,000	196,399		Sep 11 04:08 PM
RAAB MICHAEL	President & CEO	Aug 27 '24	Sale	6.22	7,500	46,635	1,219,509	Aug 28 05:45 PM
MICHAEL G. RAAB	Officer	Aug 27 '24	Proposed Sale	6.22	7,500	46,635		Aug 27 04:09 PM
SUSAN RODRIGUEZ	Officer	Aug 26 '24	Proposed Sale	6.37	72,612	462,560		Aug 26 04:49 PM
Williams Laura A	Chief Medical Officer	Aug 20 '24	Sale	5.86	7,412	43,437	314,740	Aug 22 06:28 PM
Rosenbaum David P.	Chief Development Officer	Aug 20 '24	Sale	5.86	4,969	29,120	351,510	Aug 22 06:26 PM
Rosenbaum David P.	Chief Development Officer	Aug 20 '24	Sale	5.86	2,250	13,186	156,252	Aug 22 06:26 PM
Renz Justin A	Chief Financial Officer	Aug 20 '24	Sale	5.86	5,289	30,995	295,257	Aug 22 06:25 PM
RAAB MICHAEL	President & CEO	Aug 20 '24	Sale	5.86	32,225	188,848	1,227,009	Aug 22 06:24 PM
GRAMMER ELIZABETH A	See Remarks	Aug 20 '24	Sale	5.86	7,089	41,544	192,380	Aug 22 06:22 PM
Felsch Robert Ora	See Remarks	Aug 20 '24	Sale	5.86	3,567	20,904	91,560	Aug 22 06:21 PM
Blanks Robert	See Remarks	Aug 20 '24	Sale	5.86	4,969	29,120	319,362	Aug 22 06:20 PM
Rosenbaum David P.	Chief Development Officer	Aug 20 '24	Option Exercise	0.99	20,507	20,302	179,009	Aug 20 06:59 PM
Rosenbaum David P.	Chief Development Officer	Aug 20 '24	Sale	6.00	20,507	123,042	158,502	Aug 20 06:59 PM
Rosenbaum David P.	Chief Development Officer	Aug 16 '24	Sale	5.94	20,000	118,740	356,479	Aug 20 06:59 PM
DAVID P ROSENBAUM TODSUBJECT T	Officer	Aug 16 '24	Proposed Sale	5.88	20,000	117,600		Aug 16 04:28 PM
RAAB MICHAEL	President & CEO	Aug 12 '24	Sale	5.71	1,229	7,018	1,259,234	Aug 14 06:16 PM
MICHAEL G. RAAB	Officer	Aug 12 '24	Proposed Sale	5.71	1,229	7,018		Aug 12 04:35 PM
RAAB MICHAEL	President & CEO	Jul 29 '24	Option Exercise	0.99	30,000	29,700	1,290,463	Jul 31 07:54 PM
RAAB MICHAEL	President & CEO	Jul 29 '24	Sale	5.64	30,000	169,314	1,260,463	Jul 31 07:54 PM
MICHAEL G. RAAB	Officer	Jul 29 '24	Proposed Sale	5.64	30,000	169,314		Jul 29 04:41 PM
RAAB MICHAEL	President & CEO	Jul 15 '24	Sale	5.97	7,500	44,768	1,260,463	Jul 17 05:54 PM
RAAB MICHAEL	President & CEO	Jun 28 '24	Sale	6.59	2,310	15,223	1,267,963	Jun 28 05:37 PM
Blanks Robert	See Remarks	Jun 21 '24	Sale	5.96	38,000	226,290	324,331	Jun 25 06:22 PM
RAAB MICHAEL	President & CEO	Jun 13 '24	Option Exercise	0.99	35,000	34,650	1,305,273	Jun 17 06:46 PM
RAAB MICHAEL	President & CEO	Jun 13 '24	Sale	6.65	35,000	232,743	1,270,273	Jun 17 06:46 PM
Williams Laura A	Chief Medical Officer	Jun 05 '24	Option Exercise	2.75	100,000	275,000	467,152	Jun 07 06:29 PM
Williams Laura A	Chief Medical Officer	Jun 05 '24	Sale	7.12	145,000	1,033,080	322,152	Jun 07 06:29 PM
Rosenbaum David P.	Chief Development Officer	Jun 03 '24	Sale	7.00	17,872	125,104	158,502	Jun 05 08:00 PM
RAAB MICHAEL	President & CEO	May 29 '24	Sale	6.72	7,500	50,390	1,270,273	May 31 04:31 PM
Williams Laura A	Chief Medical Officer	May 21 '24	Sale	7.81	4,794	37,446	367,152	May 23 04:21 PM
Rosenbaum David P.	Chief Development Officer	May 21 '24	Sale	7.81	4,855	37,922	376,479	May 23 04:19 PM
Rosenbaum David P.	Chief Development Officer	May 21 '24	Sale	7.81	2,198	17,169	176,374	May 23 04:19 PM
Rodriguez Susan	Chief Commercial Officer	May 21 '24	Sale	7.81	6,703	52,357	449,092	May 23 04:17 PM
Renz Justin A	Chief Financial Officer	May 21 '24	Sale	7.81	5,167	40,359	300,546	May 23 04:15 PM
RAAB MICHAEL	President & CEO	May 21 '24	Sale	7.81	31,484	245,922	1,277,773	May 23 04:13 PM
GRAMMER ELIZABETH A	See Remarks	May 21 '24	Sale	7.81	6,927	54,107	199,469	May 23 04:10 PM
Felsch Robert Ora	See Remarks	May 21 '24	Sale	7.81	3,485	27,221	95,127	May 23 04:08 PM
Blanks Robert	See Remarks	May 21 '24	Sale	7.81	4,855	37,922	362,331	May 23 04:07 PM
RAAB MICHAEL	President & CEO	May 14 '24	Sale	7.99	3,000	23,970	1,307,933	May 15 06:15 PM
Felsch Robert Ora	See Remarks	May 06 '24	Option Exercise	1.48	119,101	176,445	303,935	May 09 04:03 PM
Felsch Robert Ora	See Remarks	May 06 '24	Sale	8.81	207,988	1,831,503	95,947	May 09 04:03 PM
GRAMMER ELIZABETH A	See Remarks	May 06 '24	Option Exercise	1.87	219,937	410,787	487,930	May 09 04:03 PM
GRAMMER ELIZABETH A	See Remarks	May 06 '24	Sale	8.88	284,170	2,522,217	203,760	May 09 04:03 PM
GRAMMER ELIZABETH A	See Remarks	May 03 '24	Sale	9.00	45,000	405,000	267,993	May 07 06:24 PM
Williams Laura A	Chief Medical Officer	May 03 '24	Option Exercise	0.99	30,000	29,700	410,138	May 07 04:48 PM
Williams Laura A	Chief Medical Officer	May 03 '24	Sale	8.35	39,949	333,574	370,189	May 07 04:48 PM
RAAB MICHAEL	President & CEO	Apr 29 '24	Option Exercise	0.99	30,000	29,700	1,340,933	May 01 07:59 PM
RAAB MICHAEL	President & CEO	Apr 29 '24	Sale	6.40	30,000	192,057	1,310,933	May 01 07:59 PM
RAAB MICHAEL	President & CEO	Apr 15 '24	Sale	7.06	7,500	52,924	1,310,933	Apr 17 04:20 PM
RAAB MICHAEL	President & CEO	Apr 01 '24	Sale	7.31	1,518	11,097	1,318,433	Apr 02 04:05 PM
GRAMMER ELIZABETH A	See Remarks	Mar 20 '24	Sale	7.73	86,000	664,978	312,993	Mar 22 04:42 PM
Rosenbaum David P.	Chief Development Officer	Feb 26 '24	Sale	9.20	5,183	47,684	175,936	Feb 28 06:57 PM
Rosenbaum David P.	Chief Development Officer	Feb 20 '24	Sale	8.75	5,017	43,880	378,985	Feb 22 06:30 PM
Rosenbaum David P.	Chief Development Officer	Feb 20 '24	Sale	8.75	2,294	20,064	181,119	Feb 22 06:30 PM
Renz Justin A	Chief Financial Officer	Feb 20 '24	Sale	8.75	5,341	46,714	304,835	Feb 22 05:01 PM
RAAB MICHAEL	President & CEO	Feb 20 '24	Sale	8.75	22,917	200,439	1,319,951	Feb 22 04:58 PM
Blanks Robert	See Remarks	Feb 20 '24	Sale	8.75	5,017	43,880	368,186	Feb 22 04:58 PM
GRAMMER ELIZABETH A	See Remarks	Feb 20 '24	Sale	8.75	4,432	38,764	398,993	Feb 22 04:57 PM
Rodriguez Susan	Chief Commercial Officer	Feb 20 '24	Sale	8.75	6,928	60,594	452,795	Feb 22 04:56 PM
Felsch Robert Ora	See Remarks	Feb 20 '24	Sale	8.75	2,352	20,571	184,834	Feb 22 04:56 PM
Williams Laura A	Chief Medical Officer	Feb 20 '24	Sale	8.75	4,803	42,008	380,138	Feb 22 04:56 PM
Rosenbaum David P.	Chief Development Officer	Feb 08 '24	Sale	9.18	15,344	140,846	384,002	Feb 09 04:14 PM
Rosenbaum David P.	Chief Development Officer	Jan 08 '24	Sale	6.64	30,000	199,200	286,596	Jan 10 05:36 PM
Renz Justin A	Chief Financial Officer	Dec 26 '23	Option Exercise	0.99	75,000	74,250	407,426	Dec 28 05:44 PM
Renz Justin A	Chief Financial Officer	Dec 26 '23	Sale	6.36	225,000	1,430,122	182,426	Dec 28 05:44 PM
Rosenbaum David P.	Chief Development Officer	Dec 18 '23	Sale	6.07	5,675	34,447	316,596	Dec 20 04:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARDX

Ardelyx Inc

Upgrade your FINVIZ experience